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Abstract  
Directly measuring evidence of influenza infections is difficult, especially in low surveillance settings 
such as sub-Saharan Africa. Using a Bayesian model, we estimated unobserved infection times and 
underlying antibody responses to influenza A/H3N2 using cross-sectional serum antibody responses 
to four strains in children aged 24-60 months. Among the 242 individuals, we estimated a variable 
seasonal attack rate and found that most children had at least one infection before two years of age. 
Our results are consistent with previously published high attack rates in children. The modelling 
approach highlights how cross-sectional serological data can be used to estimate epidemiological 
dynamics.  
Keywords : Influenza, childhood infection, The Gambia , serology, Bayesian model  
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Introduction  
Influenza epidemics cause substantial global burden [1], with individuals infected with multiple viral 
strains during their lifetime [2, 3]. In sub-Saharan Africa, seasonal influenza can lead to high mortality 
and large burden of illness in children [4]. There is evidence early-life exposure to influenza viruses 
can shape both subsequent antibody responses to later strains [5] and risk of disease [6]. However, 
because infections may be asymptomatic or subclinical [7], it can be challenging to measure these 
early-life infections. Understanding of early life seasonal influenza infections in sub-Saharan Africa is 
further limited by the relative paucity of seroepidemiological studies of childhood populations.  
We tested contemporary sera from cross-sectional samples in a childhood cohort from The Gambia 
against a panel of recently circulating influenza A/H3N2 strains [8]. Combining these 
haemagglutination inhibition (HI) assays with a Bayesian model of unobserved infections and 
antibody dynamics [9, 10], we estimated the frequency and timing of infections in the cohort. We then 
used these results to reconstruct seasonal attack rates, as well as characterise antibody responses in 
children following primary infections with influenza A/H3N2.  
Materials and methods 
Study population and serological testing  
Two cohorts of unvaccinated children aged between 24 and 60 months living within a peri-urban area 
in The Gambia were recruited between February and April in 2017 (n=116), and between January and 
March in 2018 (n=126), as part of a prospective observational phase 4 study of live attenuated 
influenza vaccine (Figure 1a; see [8] for details), the total number included in the current study was 
242. The median age of the individuals across both cohorts was 35 months (range 24-59). Pre-
vaccination serum samples were taken from each participant. Each sample was tested by HI assay 
against a panel of three egg-cultured influenza A/H3N2 vaccine viruses: A/Texas/50/2012, 
A/Switzerland/9715293/2013 and A/Hong Kong/4801/2014. These were chosen to represent the main 
antigenically distinct A/H3N2 strains circulating during the lifetime of the children based on WHO 
influenza vaccine recommendations for the Northern hemisphere.  
Statistical analysis  
We used a Bayesian inference framework to jointly estimate infection histories and cross-reactive 
antibody dynamics for each participant [10]. The overall methodology is described in [9] and we detail 
the specific assumptions of our application in the supplementary information. For an unknown 
sequence of infection times from year of birth until year of sampling, a mechanistic model of antibody 
boosting, waning and cross-reaction generated a predicted antibody titre against each test strain for 
each participant. The predicted assay response (HI titre) was defined by a normally distributed 
random variable with mean equal to the predicted antibody response and standard deviation reflecting 
assay measurement error; these were interval-censored to reflect measured two-fold HI dilutions 
(supplementary information). The model also estimated a time-varying population-level probability of 
infection to account for correlation in infection risk between individuals during outbreaks. Using this 
framework, we estimated infection times and model parameters from the serological data.  
We considered infections on a quarterly timescale, (i.e. individuals could be infected once per 3-
month window), where quarters were defined as follows: Q1: 1st January to 31st March; Q2: 1st April to 
30th June; Q3: 1st July to 30th September; and Q4: 1st October to 31st December. We assumed that the 
antigenic distance between strains increased linearly with time, reflecting the locally linear average 
path of A/H3N2 antigenic evolution observed in antigenic maps of cross-reactive responses to 
A/H3N2 derived from naive ferret antisera [2, 11]. A Euclidean distance of one unit on the antigenic 
map corresponds to a two-fold reduction in HI titre between the strain that generated the antisera and 
the cross-reactive strain being measured. We assumed that there was no detectable antigenic 
change within a specific calendar year and that strains circulated according to the periods of time they 
were selected as vaccine components (Figure 1a).  
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/jid
/a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/in
fd
is
/jia
a
3
3
8
/5
8
5
9
5
8
6
 b
y
 g
u
e
s
t o
n
 0
1
 J
u
ly
 2
0
2
0
$FF
HSWH
G0
DQX
VFUL
SW
 
 
We incorporated prior information about dynamic antibody dynamic in the model. Specifically, the 
level of short-term rise in titre following infection, the rate of waning of this short-term response, and 
subsequent persistent level of titre were informed by previous analysis of HI data using the same 
model [10]. In the absence of any surveillance data from The Gambia, we incorporated prior 
knowledge about the times of infection based on epidemiological data from neighbouring Senegal 
[12]: we assumed that infection was most likely to occur in the third quarter of the year, with a very 
low probability of infection in the remaining quarters. In 2013, there was also very little H3N2 influenza 
infection reported in Senegal [12]; we therefore assumed very little infection probability in all quarters 
in 2013 (see supplementary information for more detail). Incorporating these prior assumptions in our 
model, we inferred the cross-reactive antibody dynamics and individual-level times of infections for 
FKLOGUHQLQWKHFRKRUWXVLQJWKH¶VHURVROYHU¶SDFNDJH>@)URPthese estimates we calculated the 
attack rate, as well as frequency of individual-level infections, predicted antibody responses and 
predicted assay response (HI titre) against different A/H3N2 strains.  
Results  
We estimated that influenza A/H3N2 attack rates varied considerably over the study time period. The 
2017 attack rate in cohort 2 was highest, with 47% (95% credible interval (CrI): 40-52%) of children 
infected. The second highest attack rate was in 2016, with 24% (19-29%) of cohort 2 and 33% (31-
36%) of cohort 1 infected. There were lower attack rates in 2014 and little evidence of infections in 
2013 and 2015 (Figure 1b). It was not possible to estimate the attack rate with any confidence in 
2012, because few individuals were born at this point.  
Fig 1. a) the number of individuals in each cohort with their respective birth and sampling 
month. Grey filled circles indicate the frequency of A/H3N2 infections that were observed in 
Senegal from 2013 to 2015 (obtained from [12]). b) the estimated attack rate for the Gambia 
cohorts with 95% quantile interval, c) the estimated number of infections per age in months, 
d) the estimated age at first infection in months.  
As well as estimating population-level dynamics, we could compare individual-level infection histories. 
We estimated that 45% of children sampled had one infection in their lifetime. Of those who had been 
infected, the age at first infection ranged from 0-5 years (i.e. the age range of the entire cohort), with a 
median age of 21 months (Figure 1d). Of 242 individuals sampled, we estimated 33% had more than 
one infection, with only one individual having evidence of three infections. We found that the 
individuals with more past infections tended to be older (Figure S1). The estimated time between 
infections for the individuals with more than one infection ranged from one quarter to four years (with 
61% individuals having two years between infections).  
Fig 2. Characteristic antibody profiles for different infection histories. The predicted antibody 
titres were calculated for each individual using 200 different draws from the posterior densities 
of the antibody parameters. Points indicate median and solid lines indicate 95% quantile 
intervals. Plots are the observed (black dots), predicted antibody response (no observation 
error) (yellow squares) and predicted assay response (with observation error) (green 
triangles) to the test strains when individuals were estimated to have had only one infection 
with a) A/Texas/50/2012 or b) A/Hong Kong/4801/2014 within a year of sampling. Plot c) 
shows the predicted antibody responses for hypothetical individuals sampled in 2018, that 
were infected either with A/Texas/50/2012 (infection in 2013) , A/Hong Kong/4801/2014 within 
18 months of the sampling date or A/Hong Kong/4801/2014 within 6 months of the sampling 
date.  
Individual-level log-titres predicted by the model corresponded well with observed log-titres (Figure 
2a-b). Because the model separately accounted for antibody dynamics and measurement error, it was 
possible to generate predictions for antibody response (true serum antibody levels) and assay 
response (the observed antibody titre) separately. The observed and predicted antibody titres for 
those individuals infected with A/Texas/50/2012 (Figure 2a) decrease with increasing strain circulation 
time.  
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By modelling the underlying antibody dynamics, the model was capable to capture the variation in 
observed log-titre according to when participants would have been infected. Participants with an 
inferred recent infection with A/Hong Kong/4801/2014 (n=62) (Figure 2b) had higher antibody titres 
than those infected with A/Texas/50/2012 (n=8). Although very few individuals were estimated to have 
been infected with A/Switzerland/9715293/2013, log-titres of at least 3 (equivalent to a raw titre of 
1:40) were observed for the majority of participants estimated to have had one previous infection, 
which in the model was explained by a high estimated level of cross-reaction.  
The effect of time-since-infection on predicted measurements is illustrated in Figure 2c. For the 
predicted antibody response, the level of response to an A/Hong Kong/4801/2014 infection 18 months 
from the sampling date and an A/Texas/50/2012 infection, was lower than a more recent infection with 
A/Hong Kong/4801/2014 within 6 months of the sampling date. Our model was able to capture the 
process of antibody waning with time after infection.  
Discussion  
By testing contemporary serum against strains antigenically similar to those circulating during the 
lifetime of a paediatric cohort, and adjusting for cross-reactive antibody dynamics and assay 
uncertainty using a Bayesian model, we estimated the epidemiology of childhood influenza A/H3N2 
infections in The Gambia. We found high seasonal attack rates in several years, with almost half the 
population infected in the peak year. Most children had a primary A/H3N2 infection by two years of 
age. Our range of attack rate estimates was broadly consistent with previously published estimates of 
infection risk in children from observed data; a systematic review of vaccine randomised controlled 
trials from 32 countries estimated a combined symptomatic and asymptomatic attack rate of 22.5% 
(95 %CI(9.0%, 46.0%)) [13].  
There are some limitations to our study. We imposed a quarterly timescale in our model due to the 
observation that neighbouring Senegal has a high-risk influenza season focused on a single quarter. 
As our data is cross-sectional, without this prior on timing of infection, we would not be able to infer 
differences between quarters. Though we had strong priors on the timing of infection, we did not 
enforce a strong prior on the magnitude of infection in the third quarter. Higher resolution estimates 
could be possible if multiple serological samples were collected within each year. In addition, infection 
in this study is measured as HI response, there are other assays and forms of testing which may 
confirm infection in individuals which we have reported as negative.  
We also assumed that circulating influenza viruses corresponded to the vaccine strain at the time, 
and that for A/Texas/50/2012 and A/ ong Kong/ 4801/2014, the same strain circulated for two 
consecutive years. Although seasonal influenza viruses can emerge many months ahead of the 
vaccine strain selection, epidemics were concentrated in a small portion of the year in our model and 
so the broad sequence of antigenic change observed in A/H3N2 viruses in The Gambia during 2011±
18 is unlikely to be substantially different to that assumed. For viruses which had well described egg-
adaptations, including A/Switzerland/9715293/2013 and A/Hong Kong/4801/2014, we anticipate HI 
titres would be smaller in magnitude compared to if the viruses tested were more similar to the actual 
circulating virus. This would mean that our inferred attack rates are lower than the true attack rates.  
Previous studies have found longitudinal data is required to reliably estimate waning antibody 
responses [3]. We therefore incorporated prior information on the relative magnitudes of short- and 
long-term antibody responses, with a strong prior on the rate of waning. However, our final estimates 
for the boost in titre following infection were generally higher than the prior estimate, suggesting 
sufficient information in the data to estimate child-specific magnitudes of response (Figure S2). We 
assumed a common waning rate for both adults and children. In reality, this rate may be different in 
children and adults, but in the absence of a robust estimate for children only, we chose to use an 
inferred waning rate from a mixed age cohort. Previous studies have shown that in mixed age cohorts 
that the waning rate is close to a year, hence it is likely that within the timescales we are using that 
any differences in waning rate would not make a substantial difference to inferred attack rates. Our 
attack rates estimates were robust to prior information on waning only (Figure S4). We also 
incorporated prior information about the timing of infection within a year, with the low attack estimated 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/jid
/a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/in
fd
is
/jia
a
3
3
8
/5
8
5
9
5
8
6
 b
y
 g
u
e
s
t o
n
 0
1
 J
u
ly
 2
0
2
0
$FF
HSWH
G0
DQX
VFUL
SW
 
 
rate in 2013 (median 0 in both cohorts) informed by Senegal surveillance data [12]. In the absence of 
this prior information in 2013, there was little difference in the estimated attack rates (Figure S5).  
Early-life infections are important for influenza, but have been historically challenging to measure. 
Applying modelling frameworks to data generated by testing contemporary sera tested against 
multiple historical strains opens up the possibility of estimating epidemiological dynamics in a wide 
variety of settings. Using our methods, this could be achieved either through new serological surveys 
or secondary analysis of existing serum banks [14]. This may be especially important in countries 
where there is a paucity of influenza surveillance and incidence data, yet where details of influenza 
attack rates are vital for planning public health policy around influenza prevention. In addition to 
providing insight into population- and individual-level risk, knowledge of unobserved prior infections 
could be a useful predictor variable in analysis of subsequent infection risk, disease risk, or responses 
to vaccination, given the increasing evidence for immune imprinting during childhood on these 
parameters [6].  
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